This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those previously on endocrine therapy, receive 5 SABR treatments, followed by monitoring of quality of life and assessment of treatment-related toxicity.
Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
Women greater than or equal to age 65 years
Diagnosis of invasive carcinoma of breast undergoing non-operative management
Previously untreated OR previously treated with primary ET or chemotherapy, with either stable or progressive localized disease.
Active treatment with systemic chemotherapy for breast cancer. Subjects will need to stop any breast cancer chemotherapy agent before enrollment to be included study.
Multicentric tumor.
Clinical or imaging evidence of distant metastases.
Prior ipsilateral breast or thoracic radiation.